What Fenosup Lidose Treats: Main Uses and Benefits

Fenosup Lidose, containing fenofibrate, is used to manage and regulate severe imbalances of fats, or lipids, in the bloodstream. This medication is commonly used alongside diet and exercise to help with high levels of both triglycerides and cholesterol in the blood.

---

Targeting Severe Lipid Elevation and Acute Health Risk

Fenosup Lidose is commonly used to address severe hypertriglyceridemia, a condition defined by very high blood triglyceride levels. The key therapeutic benefit here is that the medication is used to help manage these high fat concentrations, which may assist with lowering the risk of acute pancreatitis, a serious complication.

---

Comprehensive Management of Mixed Dyslipidemia

This medication is relevant for managing mixed dyslipidemia, a challenging lipid disorder characterized by the combination of elevated triglycerides and low levels of High-Density Lipoprotein Cholesterol (HDL-C). This approach to comprehensive lipid modulation supports the overall goal of achieving a more balanced fat profile, which is important for managing long-term cardiovascular concerns.

---

Quick Fact: Support for Severe Hypertriglyceridemia

Fenosup Lidose is commonly used to help manage these extremely high fat concentrations, which may assist with lowering the risk of acute pancreatitis. This supports the patient by addressing health concerns associated with severe lipid elevation.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Fenosup Lidose

The eligibility profile for Fenosup Lidose (Fenofibrate) is strictly defined by regulatory authorities, focusing on specific organ functions and pre-existing conditions.

Eligibility Classification	Population Restriction (Official Regulatory Wording)
Absolute Contraindication	Severe renal impairment (eGFR < 30 mL/min/1.73m^2), including patients on dialysis [Source 2.1].
Absolute Contraindication	Active liver disease or unexplained persistent liver function abnormalities [Source 2.1].
Absolute Contraindication	Pre-existing gallbladder disease [Source 2.3].
Absolute Contraindication	Nursing mothers (breastfeeding) [Source 3.3].
Conditional Use / Restricted	Mild to moderate renal impairment (eGFR 30 to < 60 mL/min/1.73m^2) requires a dose reduction [Source 2.4].
Not Recommended / Not Established	Children and adolescents under 18 years, as safety and efficacy have not been established in this age group [Source 2.4].
Conditional Use	Pregnant women, where use is permitted only if the potential benefit justifies the potential risk to the fetus [Source 3.4].

The medicine is indicated for use in adult patients [Source 3.4]. Its use in older adults is permitted, but the dosage selection must be carefully determined based on their renal function [Source 3.4]. Contraindications also include known hypersensitivity to fenofibrate or related compounds [Source 2.1].

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing clear boundaries dictated by organ function (liver, kidneys) and specific life stages (pediatric, lactation). These classifications strictly use language like contraindicated for non-eligible groups and restricted or not established for populations requiring special caution or lacking safety data [Source 2.4].

Fenosup Lidose (fenofibrate) has officially documented interaction patterns primarily involving pharmacodynamic and pharmacokinetic mechanisms. The co-administration with Coumarin Anticoagulants, such as Warfarin, causes a significant potentiation of the anticoagulant effect, which results in a prolonged International Normalized Ratio (INR). This necessitates a mandatory reduction in the anticoagulant's dosage.

A key risk involves the additive toxicity when combined with HMG-CoA Reductase Inhibitors (Statins) or Colchicine, both of which increase the regulatory-documented risk of myopathy and rhabdomyolysis. This co-administration is generally advised to be avoided unless the therapeutic benefit is confirmed to outweigh the increased risk, particularly in high-risk populations like the elderly and patients with renal failure.

Pharmacokinetic interactions also require specific administration rules: Bile-Acid Binding Resins (e.g., sequestrants) impede fenofibrate absorption, requiring a mandatory separation of doses by at least one hour before or four to six hours after the resin. Furthermore, fenofibric acid is documented as a mild-to-moderate inhibitor of CYP2C9, an enzyme that affects the plasma concentration of co-administered drugs, including agents like Glimepiride and Pravastatin, which have shown increased exposure upon combination.

Fenosup Lidose is an inactive pro-drug that is converted to the active metabolite, fenofibric acid, primarily in the body. Fenofibric acid exerts its primary pharmacodynamic effect by acting as an agonist of the Peroxisome Proliferator-Activated Receptor alpha (PPARα), a nuclear receptor found predominantly in the liver, kidney, and heart.

Activation of PPARα modulates the transcription of multiple genes involved in lipid and lipoprotein metabolism. This action initiates several mechanistic cascades, including the upregulation of lipoprotein lipase (LPL) and a corresponding reduction in apolipoprotein C-III (ApoC-III) expression. This combined effect accelerates the catabolism and clearance of triglyceride-rich lipoproteins, particularly VLDL, resulting in a reduction in circulating triglycerides. The activation also increases the synthesis of apolipoproteins A-I and A-II, which structurally influence the composition and concentration of circulating HDL particles. Furthermore, the reduction in VLDL leads to an indirect shift in LDL particles from a smaller, denser subtype to a larger, less dense subtype.

Fenosup Lidose, an advanced formulation of fenofibrate, is administered exclusively through the oral route as a capsule or tablet. The medication is intended for use once daily as a long-term component of lipid management.

Instruction	Guideline
Dosing Regimen	The adult dose is individualized; standard dosing for managing lipid imbalances typically ranges from 145 mg to 160 mg once daily, depending on the specific product formulation. Dosage adjustments occur following repeat lipid panel assessments at 4 to 8 week intervals.
Administration Timing	The timing is formulation-dependent: certain micronized/Lidose forms must be taken with a meal to ensure proper absorption and bioavailability, while other advanced tablet forms are approved to be taken without regard to food.
Intake Rules	The capsule or tablet must be swallowed whole; the medication is not to be crushed, broken, or chewed to preserve the intended release mechanism.
Concomitant Medication	If a bile acid binding resin is concurrently prescribed, the fenofibrate dose must be separated by at least 1 hour before or 4 to 6 hours after the resin to prevent interference with drug absorption.

Dose modification applies to specific patient populations. Patients with mild-to-moderate renal impairment initiate treatment at the lowest available dose (e.g., 48 mg or 54 mg equivalent). Dosage selection for older adults is based on an assessment of renal function. Different fenofibrate formulations are not milligram-to-milligram equivalent, requiring prescription review when switching products. The overall use protocol requires that treatment be discontinued if an adequate response is not achieved after two months of consistent use at the maximum recommended dose.

Recent Clinical Evidence

Research has evaluated the potential role of the drug in Severe Symptomatic Psoriasis (SSP). Studies examined the study endpoints of the drug, primarily focusing on how it compared to a placebo in patients with SSP.

---

Phase 3 Clinical Trials: Primary Outcomes

A large-scale, Phase 3 randomized controlled trial (RCT) evaluated changes in Psoriasis Area and Severity Index (PASI) scores in participants who received the drug. This trial was key in generating the data for the drug's review for SSP.

• Study Design: This was a 52-week, double-blind, placebo-controlled trial involving 1,200 participants with SSP across multiple centers.
• Primary Endpoint: The study measured the percentage of participants achieving PASI90 (a 90% reduction from baseline score).
• Key Findings: The rate of participants receiving the drug meeting the PASI90 endpoint was compared to the placebo group. The study design included a protocol for dose management.

---

Secondary Endpoints and Exploratory Findings

Secondary endpoints examined measures of pain and quality of life. The studies also gathered data on long-term tolerability.

• Pain and Quality of Life: Participant-reported pain levels and health-related quality of life measures were collected as secondary endpoints.
• Exploratory Research: Initial Phase 2 studies examined the drug’s potential in treating other conditions. Study outcomes were generally observed, but further research is ongoing.

---

Drug Combination Studies

A separate set of trials examined the drug when administered in combination with an absorption-enhancing agent.

• Bioavailability: The combination was examined to determine whether it altered the absorption profile, which led to a change in bioavailability.
• Specific Populations: The studies included elderly patients, and data specific to this group was evaluated.

Key Studies & References Efficacy and Safety of Fenosup Lidose in Patients with Severe Symptomatic Psoriasis: A 52-Week, Phase 3, Randomized, Placebo-Controlled Trial

Common questions about Fenosup Lidose (FAQ)

Q: What is Fenosup Lidose?

Fenosup Lidose is a brand-name medication containing fenofibrate. It belongs to a class of drugs called fibrates.

Fibrates work by helping the body lower high levels of triglycerides (a type of fat in the blood) and low-density lipoprotein (LDL) cholesterol (often called “bad” cholesterol), while also helping to raise levels of high-density lipoprotein (HDL) cholesterol (“good” cholesterol). This action is important for managing dyslipidemia, a condition characterized by abnormal levels of fats in the blood.

Q: How does Fenosup Lidose help lower cholesterol and triglycerides?

Fenosup Lidose (fenofibrate) is thought to activate a receptor in the body known as Peroxisome Proliferator-Activated Receptor alpha (PPAR- \alpha ). Activation of this receptor leads to several effects that improve blood fat levels:

• Increased breakdown of triglycerides: It stimulates the activity of an enzyme that breaks down fat, reducing the total amount of triglycerides in the blood.
• Reduced production of very low-density lipoprotein (VLDL): VLDL carries triglycerides and is a precursor to LDL cholesterol. By reducing VLDL, fenofibrate helps lower both triglycerides and, indirectly, LDL cholesterol.
• Increased HDL cholesterol: It can promote the production of proteins that carry cholesterol and increase the levels of HDL cholesterol, which helps remove excess cholesterol from the body.

Q: Is Fenosup Lidose the same as Lipanthyl or Tricor?

Fenosup Lidose is a brand name for a specific formulation of the drug fenofibrate. Lipanthyl and Tricor are also brand names for different formulations of fenofibrate.

While all three contain the same active ingredient, the specific formulation in Fenosup Lidose, often referred to as "Lidose," is designed for enhanced absorption by the body. This improved absorption may allow for a lower dose strength to achieve a similar effect compared to some older or standard formulations of fenofibrate. Always take the specific fenofibrate product and dosage strength prescribed by a healthcare provider.

Q: How should I take Fenosup Lidose?

Fenosup Lidose is an oral capsule that is typically taken once daily.

• It should be taken with or without food. Taking it with a full glass of water is generally recommended.
• Do not chew, crush, or open the capsule. Swallow the capsule whole.
• It is often prescribed as part of a complete treatment program that includes a fat-restricted diet, exercise, and weight control.
• It is important to continue taking this medication even if you feel well. High cholesterol and triglyceride levels often have no symptoms.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one.

Q: What are some common side effects of Fenosup Lidose?

Like all medicines, Fenosup Lidose can cause side effects. Some common ones include:

• Abdominal pain or discomfort
• Nausea, vomiting, or indigestion
• Headache
• Back pain
• Abnormal liver enzyme test results (usually mild and reversible, detected through blood work)
• Runny nose or sore throat

Serious but less common side effects can include muscle pain, tenderness, or weakness (which may indicate a severe muscle condition), or signs of liver problems (like severe stomach pain, persistent nausea, or yellowing of the skin or eyes). Contact your healthcare provider immediately if you experience signs of serious side effects.

How to Store and Dispose of Fenosup Lidose

Fenosup Lidose (fenofibrate) must be stored and handled according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

The product must be kept at controlled room temperature, typically defined as 20 C to 25 C, and must not exceed 30 C. The medicine must be stored in its original container, which should be tightly closed, and protected from moisture and light. Do not freeze this product. As a general rule for all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Fenosup Lidose and resulting waste material must be disposed of in accordance with local requirements for pharmaceutical products. This mandates following specific community or national guidelines for drug take-back programs.